Conference Coverage

Laparoscopic surgery survival outcomes on par with open approach in colorectal liver metastases


 

REPORTING FROM ASCO 2019

– For colorectal cancer patients with liver metastases, laparoscopic surgery has short-term advantages over open surgery, including fewer complications and better quality of life as compared to open surgery. Now, there are data to show that long-term outcomes with the laparoscopic approach aren’t any worse with the laparoscopic approach.

In a video interview at the annual meeting of the American Society of Clinical Oncology, Åsmund Avdem Fretland, MD, discusses results of the 280-patient randomized OSLO-COMET study, including 5-year survival of 56% for the laparoscopic approach, and similarly, 57% for the open procedure.

Based on lower morbidity, and now similar life expectancy, more centers should be doing laparoscopic procedures for liver metastases, said Dr. Fretland, a surgeon in the department of HPB surgery at Oslo University Hospital.

For now, however, open surgery appears to be the dominant approach. According to a recent survey, just 22% of U.S. patients with colorectal liver metastases have laparoscopic surgery.

More data could help. Dr. Fretland said in the interview that more randomized trials are underway aimed at evaluating the long-term outcomes of laparoscopic versus open procedures.

Dr. Fretland reported honoraria from Olympus Medical Systems.

Recommended Reading

Robotic and lap surgery achieve similar negative margins for rectal resection
MDedge Hematology and Oncology
Pancreatic cancers often contained targetable mutations
MDedge Hematology and Oncology
Low-dose chemo feasible for older, frail patients with advanced gastroesophageal cancer
MDedge Hematology and Oncology
In duodenal neuroendocrine tumors, resection technique matters
MDedge Hematology and Oncology
Enzalutamide in castration-sensitive prostate cancer and ctDNA to monitor early colorectal cancer
MDedge Hematology and Oncology
SEER data show that pancreatic cancer mortality rates differ by ethnicity
MDedge Hematology and Oncology
Pembro as good as chemo for gastric cancers with less toxicity
MDedge Hematology and Oncology
Maintenance olaparib extends PFS in pancreatic cancer with BRCA mutation
MDedge Hematology and Oncology
Adjuvant CAPOX: Three months may be as good as 6 in high-risk stage II colon cancer
MDedge Hematology and Oncology
Pembrolizumab missed statistical cutoffs in hepatocellular carcinoma study
MDedge Hematology and Oncology